Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p‐tau as screening instruments

Participants with unimpaired or mildly impaired cognition were grouped based on cutoffs on genetic risk factors (G: polygenic hazardous score [PHS]) and Alzheimer's pathology (T: baseline plasma phosphorylated tau-181 [p-tau181]). Participants with high PHSs and plasma p-tau181 levels (G+T+) were at risk of faster cognitive decline and AD progression. The combination of PHS and plasma p-tau181 could enhance clinical trial enrichment more effectively than using single biomarkers.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-10-23
DOI
https://doi.org/10.1002/alz.14284
Citations
1
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p‐tau as screening instruments

Sarah Jane Banks, Anders M. Dale, Iris Broce, Steven D. Edland et al.
1 citations
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
0.39
article

Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p‐tau as screening instruments

Sarah Jane Banks, Anders M. Dale, Iris Broce, Steven D. Edland, Xinran Wang, Xin Wang
article en
1 citations

Abstract

Participants with unimpaired or mildly impaired cognition were grouped based on cutoffs on genetic risk factors (G: polygenic hazardous score [PHS]) and Alzheimer's pathology (T: baseline plasma phosphorylated tau-181 [p-tau181]). Participants with high PHSs and plasma p-tau181 levels (G+T+) were at risk of faster cognitive decline and AD progression. The combination of PHS and plasma p-tau181 could enhance clinical trial enrichment more effectively than using single biomarkers.

Alzheimer s & DementiaVol. 20(12)
University of California San Diego (US), Human Longevity (United States) (US)
U.S. Department of Defense, U.S. Department of Veterans Affairs, Alzheimer's Association, Eli Lilly and Company, Brigham and Women's Hospital, Massachusetts General Hospital, Biogen, University of Southern California, Vanderbilt University, University of Pennsylvania, Ohio State University, Northwestern University, Wake Forest University, Cleveland Clinic, Alzheimer's Disease Neuroimaging Initiative, University of Washington, University of Pittsburgh, Georgetown University, Case Western Reserve University, Dartmouth College, Rush University, Northern California Institute for Research and Education, Vanderbilt University Medical Center, University College London, National Institutes of Health, University of California, Davis, University of California, San Diego, Perelman School of Medicine, University of Pennsylvania, University of California, San Francisco, Feinberg School of Medicine, University of California, Irvine, School of Medicine, Indiana University, Houston Methodist Research Institute, National Institute of Mental Health
Openalex Percentile: Top 34%
Dementia and Cognitive Impairment Research
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.